Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2005 1
2006 3
2007 1
2009 1
2011 1
2014 1
2015 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Abnormal insulin like growth factor binding protein acid labile subunit level"
Page 1
Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences.
Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG; International ALS Collaborative Group. Domené HM, et al. Horm Res. 2009;72(3):129-41. doi: 10.1159/000232486. Epub 2009 Sep 1. Horm Res. 2009. PMID: 19729943 Free article. Review.
Fourteen different mutations of the human IGFALS gene have been identified in 17 patients, suggesting that ALS deficiency may be prevalent in a subset of patients with extraordinarily low serum levels of IGF-I and IGFBP-3 that remain abnormally low upon growth hormo …
Fourteen different mutations of the human IGFALS gene have been identified in 17 patients, suggesting that ALS deficiency may be prevalent i …
IGF-I-IGFBP-3-acid-labile subunit (ALS) complex in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH).
Völkl TM, Rauh M, Schöfl C, Dörr HG. Völkl TM, et al. Growth Horm IGF Res. 2011 Aug;21(4):191-8. doi: 10.1016/j.ghir.2011.05.001. Epub 2011 Jun 1. Growth Horm IGF Res. 2011. PMID: 21636299 Clinical Trial.
It has been shown that changes in IGF-I and IGFBP levels in children with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) are correlated with different states of metabolic control. ...All patients had genetically proven CAH and receiv …
It has been shown that changes in IGF-I and IGFBP levels in children with classical congenital adrenal hyperplasia due to 21-h …
Noonan syndrome: relationships between genotype, growth, and growth factors.
Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y. Limal JM, et al. J Clin Endocrinol Metab. 2006 Jan;91(1):300-6. doi: 10.1210/jc.2005-0983. Epub 2005 Nov 1. J Clin Endocrinol Metab. 2006. PMID: 16263833
Birth length was reduced [mean -1.2 sd score (SDS); six m+ and two m- were < -2 SDS] but not birth weight. ...M- patients. ALS levels (n = 10) were also very low. By contrast, the mean basal IGFBP-3 value (n = 19) was normal. ...

Birth length was reduced [mean -1.2 sd score (SDS); six m+ and two m- were < -2 SDS] but not birth weight. ...M- patients. ALS

…
IGFALS gene dosage effects on serum IGF-I and glucose metabolism, body composition, bone growth in length and width, and the pharmacokinetics of recombinant human IGF-I administration.
Högler W, Martin DD, Crabtree N, Nightingale P, Tomlinson J, Metherell L, Rosenfeld R, Hwa V, Rose S, Walker J, Shaw N, Barrett T, Frystyk J. Högler W, et al. J Clin Endocrinol Metab. 2014 Apr;99(4):E703-12. doi: 10.1210/jc.2013-3718. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423360 Clinical Trial.

RESULTS: IGF-I and IGFBP-3 increased above baseline (P < .05) for 2.5 hours, returning to baseline 7 hours after rhIGF-I injection. Mean (SD) IGF-I Z-score increased by 2.49 (0.90), whereas IGFBP-3 Z-score increased by 0.57 (0.10) only. ...Bone analysis showed th

…

RESULTS: IGF-I and IGFBP-3 increased above baseline (P < .05) for 2.5 hours, returning to baseline 7 hours after rhIGF-I injection. Mean

…
IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
Bakker NE, van Doorn J, Renes JS, Donker GH, Hokken-Koelega AC. Bakker NE, et al. J Clin Endocrinol Metab. 2015 Aug;100(8):3041-9. doi: 10.1210/jc.2015-1410. Epub 2015 May 29. J Clin Endocrinol Metab. 2015. PMID: 26050733
RESULTS: Serum IGF-1, IGFBP-3, and ALS levels and IGF-1 to IGFBP-3 ratio were significantly higher in GH-treated PWS children than in healthy controls. ...IGF bioactivity during GH showed a wide variation, and there was a disrupted correlation with immunoreactive IGF-1 …
RESULTS: Serum IGF-1, IGFBP-3, and ALS levels and IGF-1 to IGFBP-3 ratio were significantly higher in GH-treated PWS children than in …
Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.
Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, Juul A. Yu H, et al. J Clin Lab Anal. 1999;13(4):166-72. doi: 10.1002/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO;2-X. J Clin Lab Anal. 1999. PMID: 10414596 Free PMC article.
There was little difference in IGF-II levels between genders. IGFBP-2 levels declined with age from birth to puberty. ...Freeze-thaw treatment up to five cycles had little impact on plasma levels of IGFs and IGFBP-3. Our observations suggest that le …
There was little difference in IGF-II levels between genders. IGFBP-2 levels declined with age from birth to puberty. ...Freez …
Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure.
Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG. Hwa V, et al. J Clin Endocrinol Metab. 2006 May;91(5):1826-31. doi: 10.1210/jc.2005-2842. Epub 2006 Feb 28. J Clin Endocrinol Metab. 2006. PMID: 16507628
OBJECTIVE: We investigated a case of IGFD in which serum IGF-I and IGFBP-3 were abnormally low, yet growth failure was modest (-2.1 sd score at 15.5 yr of age). RESULTS: The young male subject, from a consanguineous pedigree, had a postnatal growth profile consisten …
OBJECTIVE: We investigated a case of IGFD in which serum IGF-I and IGFBP-3 were abnormally low, yet growth failure was modest (-2.1 s …
Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy?
Savage MO, Camacho-Hübner C, David A, Metherell LA, Hwa V, Rosenfeld RG, Clark AJ. Savage MO, et al. Eur J Endocrinol. 2007 Aug;157 Suppl 1:S33-7. doi: 10.1530/EJE-07-0292. Eur J Endocrinol. 2007. PMID: 17785695 Review.
CONCLUSIONS: Analysis for single-gene defects does not give sensitive predictions of phenotype and cannot predict responses to GH or IGF-I therapy. Endocrine abnormalities have closer correlations with phenotype and may thus be a better guide to therapeutic r …
CONCLUSIONS: Analysis for single-gene defects does not give sensitive predictions of phenotype and cannot predict responses to …
Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity.
Shapiro L, Chatterjee S, Ramadan DG, Davies KM, Savage MO, Metherell LA, Storr HL. Shapiro L, et al. Eur J Endocrinol. 2017 Dec;177(6):485-501. doi: 10.1530/EJE-17-0453. Epub 2017 Sep 4. Eur J Endocrinol. 2017. PMID: 28870985
IGF-1 insensitivity results in pre- and post-natal growth failure with normal/high IGF-1 levels. The prevalence of genetic defects is unknown. OBJECTIVE: To identify the underlying genetic diagnoses in a paediatric cohort with GH or IGF-1 insensitivity using candidate gene …
IGF-1 insensitivity results in pre- and post-natal growth failure with normal/high IGF-1 levels. The prevalence of genetic defects is …
The correlation of the IGF-I, IGFBP-3, and ALS generation test to height velocity after 6 months of recombinant growth hormone therapy in girls with Turner syndrome.
Collett-Solberg PF, Pessoa de Queiroz AN, Cardoso ME, Jusan RC, Vaisman M, Guimarães MM. Collett-Solberg PF, et al. Growth Horm IGF Res. 2006 Aug;16(4):240-6. doi: 10.1016/j.ghir.2006.06.002. Growth Horm IGF Res. 2006. PMID: 16908209 Clinical Trial.
Levels of IGF-I and IGFBP-3 were measured before and 5, 30 and 90 days after starting hGH (0.05 mg/kg/day), ALS levels were measured only prior and after 5 days. ...Most of the data was too scattered to be used individually for each patient. CONCLUSIONS: Even though …
Levels of IGF-I and IGFBP-3 were measured before and 5, 30 and 90 days after starting hGH (0.05 mg/kg/day), ALS levels were me …